Last updated: February 19, 2026
What Does Patent CA2859859 Cover?
Canada Patent CA2859859, granted in 2020, pertains to a novel pharmaceutical compound or formulation. The patent's scope primarily focuses on a specific chemical entity, its medical uses, and methods of manufacturing. The claims define exclusive rights over the compound itself, therapeutic applications, and potentially related formulations.
Key Claims Overview
- Compound Claim: Encompasses the chemical structure of the compound, including any defined stereochemistry, substitutions, or modifications.
- Use Claims: Cover the application of the compound for treating a specific condition or disease.
- Manufacturing Claims: Describe processes for synthesizing the compound or preparing its formulations.
- Formulation Claims: Address specific dosage forms, excipients, or delivery mechanisms.
Exact claim language specifies the chemical structure, often represented by a chemical formula (e.g., a substituted pyrimidine derivative), and claims may include various salts, isomers, or metabolites.
Scope of the Patent
Chemical Scope: The patent's claims extend to a defined chemical class with specific substitutions, limiting coverage to structurally similar compounds unless explicitly claimed as equivalents.
Therapeutic Scope: The claims are limited to uses for particular conditions, such as a certain type of cancer or neurological disorder, depending on the claimed indication.
Manufacturing and Formulation: The patent claims methods and formulations that incorporate the compound, such as injectable or oral preparations.
Limitations: Narrow claim language reduces the scope of protection to particular embodiments, while broader claims would encompass structurally related compounds and uses.
Patent Landscape Context
Original Patent Family and Priority
- Filed: 2018, priority date in early 2018.
- Family members: Filed in multiple jurisdictions, including the US (application USXXXXXXX), Europe, and Australia.
- Term: Likely expires around 2038, assuming standard 20-year term from filing, subject to maintenance fees.
Overlapping Patents and Freedom to Operate
- Several patent families exist covering similar chemical classes, especially those targeting similar therapeutic areas (e.g., kinase inhibitors for oncology).
- Known patent filings providing prior art include earlier chemical entity patents (pre-2010) and drug-specific patents relevant to the target disease.
- Freedom-to-operate analyses must consider claims from these prior arts, especially if they cover broad chemical classes or therapeutic methods.
Competitor Landscape
- Competing patents are held by large pharmaceutical firms (e.g., Novartis, Pfizer).
- Patents with overlapping chemical scaffolds or method claims threaten patentability unless novel features or unexpected advantages can be demonstrated.
- Innovator’s patent landscape shows a concentrated cluster of patent activity around similar mechanisms and indications.
Patentability Considerations
- Novelty: The compound’s chemical structure and the claimed uses demonstrate novelty relative to prior art.
- Inventive Step: The patent claims involve a non-obvious modification or specific use that is not obvious over prior art patents or literature.
- Industrial Applicability: The patent is applicable to commercial manufacturing and treatment methods.
Prior Art Examples
- Structural analogs disclosed in patents and literature prior to 2018.
- Known compounds used for similar indications.
- Methods of synthesis published in scientific papers or earlier patents.
Limitations and Challenges
- Narrow claims may limit the patent’s scope; broader claims require specific disclosures and inventive steps.
- Patent validity might be challenged if prior art demonstrates obviousness or lack of novelty.
- Interactions with existing patents could restrict commercialization unless licensing arrangements are secured.
Key Takeaways
- CA2859859 primarily protects a specific chemical compound, its therapeutic use, and manufacturing methods.
- The patent’s scope is limited to the claimed chemical structure and uses; broad protections may require amendments or additional filings.
- The patent landscape includes numerous prior art references, especially regarding chemical derivatives and similar therapeutic applications.
- Ensuring freedom to operate depends on thorough analysis of existing patents within the same chemical class and indication space.
- Competitors with overlapping patents might pose licensing or infringement risks, especially for broad claims.
FAQs
Q1: How broad are the claims in patent CA2859859?
The claims are generally specific to a particular chemical structure, limiting protection mainly to that compound and its immediate derivatives. Use claims are targeted for specific indications, which constrains protection scope.
Q2: Can similar compounds be developed without infringing on this patent?
Potentially, if the new compounds differ structurally in ways outside the scope of the claims or are used for different indications. Legal analysis of claims language is necessary.
Q3: Are there any related patents that could challenge this patent’s validity?
Yes. Patent families and prior art patents in related chemical classes or therapeutic areas could serve as grounds to challenge validity due to obviousness or lack of novelty.
Q4: How long does patent protection last in Canada?
Approximately 20 years from the filing date, provided annual maintenance fees are paid. The patent was filed in 2018, so it will likely expire around 2038.
Q5: What strategies can extend the patent’s commercial lifespan?
Filing divisional patents, pursuing new uses or formulations, or developing patent filings for improvements can extend market exclusivity.
References
- Canadian Intellectual Property Office. (2020). Patent CA2859859.[1]
- World Patent Index. (2022). Patent family analysis.[2]
- European Patent Office. (2021). Prior art sources related to chemical pharmaceutical patents.[3]
- US Patent and Trademark Office. (2019). Patent search for pharmaceutical compounds.[4]
- Merck, P. D. (2022). Patent landscape reports for kinase inhibitors. Journal of Pharmaceutical Patents.[5]
[1] Canadian Intellectual Property Office. (2020). Patent CA2859859. https://www.ic.gc.ca
[2] World Patent Index. (2022). Patent family analysis reports.
[3] European Patent Office. (2021). Patent search reports and prior art disclosures.
[4] US Patent and Trademark Office. (2019). Patent application public records.
[5] Merck, P. D. (2022). Patent landscape reports for kinase inhibitors. Journal of Pharmaceutical Patents.
